DEF: Shattuck Labs Schedules 2026 Annual Meeting

Shattuck Labs announces its 2026 Annual Meeting of Stockholders, detailing proposals including director elections, auditor ratification, executive compensation votes, and equity plan amendments.

Summary

• Shattuck Labs, Inc. will hold its 2026 Annual Meeting of Stockholders virtually on May 28, 2026, at 11:30 a.m. Eastern Time.
• Key proposals include the election of three Class III directors, ratification of KPMG LLP as the independent auditor for 2026, an advisory vote on executive compensation, an advisory vote on the frequency of future executive compensation votes, and the approval of an amendment and restatement of the 2020 Equity Incentive Plan.
• The record date for determining stockholders entitled to vote is April 2, 2026, with 75,581,787 shares of common stock outstanding as of that date.
• The company is providing proxy materials primarily via the internet to reduce costs and environmental impact.
• The Board of Directors recommends voting FOR the director nominees, FOR the ratification of the auditor, FOR the executive compensation approval, for a ONE YEAR frequency for future compensation votes, and FOR the amendment of the equity incentive plan.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, as it outlines standard corporate governance procedures and proposals for the annual meeting, including an equity plan amendment designed to support talent retention. However, the inclusion of pre-funded warrants in equity calculations hints at potential future dilution, which warrants careful monitoring.

Positives

• The company is holding its annual meeting to ensure continued corporate governance and stockholder engagement.
• The virtual meeting format aims to increase accessibility for all stockholders.
• The proposed amendment to the 2020 Equity Incentive Plan aims to ensure sufficient share reserves for employee retention and attraction.
• The company has a robust board structure with independent directors and established committees (Audit, Compensation, Nominating and Corporate Governance).

Negatives

• Two Form 4 filings for Dr. Ashiya and OrbiMed were filed late due to administrative error, indicating potential minor compliance oversights.
• The amendment to the equity incentive plan is partly driven by a significant increase in unexercised pre-funded warrants (40% of total equity), which could indicate dilution concerns for common stockholders if not managed carefully.

Risks

• The Proxy Statement may contain forward-looking statements subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed.
• The amendment to the 2020 Equity Incentive Plan aims to adjust share reserve calculations to include shares underlying unexercised pre-funded warrants and preferred stock, which could lead to increased dilution.
• The company's business is subject to the risks described in its most recent Form 10-K and subsequent SEC filings, which are not detailed in this proxy statement.

Future Outlook

The company is seeking stockholder approval for an amendment and restatement of its 2020 Equity Incentive Plan, which includes changes to the basis for annual share increases and an extension for granting incentive stock options. The plan aims to ensure sufficient share reserves for employee retention and attraction.

Management Comments

• The Board of Directors has fixed April 2, 2026 as the record date.
• The Board believes that separating the roles of Chairman and CEO, with an independent Chairman, enables effective oversight of corporate governance and business leadership.
• Management recommends voting FOR each director nominee, FOR ratification of the independent auditor, FOR the advisory vote on executive compensation, for a ONE YEAR frequency for future advisory votes on executive compensation, and FOR the amendment and restatement of the 2020 Equity Incentive Plan.

Industry Context

StockSavvy.ai notes that Shattuck Labs' proxy statement reflects standard corporate governance practices for a publicly traded biotechnology company, including proposals for director elections, auditor ratification, and executive compensation. The proposed amendment to the equity incentive plan, which considers pre-funded warrants in share reserve calculations, is a notable adjustment in response to financing activities and potential dilution management.

Comparison to Industry Standards

• The structure of the Board of Directors, with independent committees (Audit, Compensation, Nominating and Corporate Governance), aligns with best practices for publicly traded companies.
• The compensation philosophy of attracting, retaining, and motivating executive talent through incentives tied to performance and shareholder value is a common approach in the biotechnology sector.
• The use of a virtual meeting format for the annual stockholder meeting is increasingly common across industries, including biotech, to enhance accessibility and reduce costs.
• The proposed amendment to the equity incentive plan, which adjusts the share reserve calculation to include shares underlying pre-funded warrants, is a response to specific financing events and reflects a common challenge in managing equity dilution in growth-stage companies.

Corporate Governance

Related Party Transactions

• In August 2025, Shattuck Labs conducted a private placement where certain beneficial owners of more than 5% of common stock, directors, and officers participated on the same terms as other purchasers. This included participation from entities affiliated with OrbiMed (director Dr. Ashiya), Prosight Management, LP, Adage Capital Partners LP, and entities affiliated with Redmile (former director Michael Lee). Executive officers and directors also participated.
• The company entered into a Registration Rights Agreement with purchasers of the private placement, granting them registration rights for shares issuable upon exercise of warrants.
• The company entered into a Letter Agreement with OrbiMed Advisors LLC in connection with a securities purchase agreement, which led to the appointment of directors Dr. Ashiya and Dr. Baker to the Board.

Stakeholder Impact

• Shareholders: Voting rights on key corporate matters, potential impact from equity incentive plan amendments (dilution), and advisory votes on executive compensation.
• Employees: Eligibility for equity awards under the 2020 Equity Incentive Plan, which is proposed for amendment.
• Directors: Election of nominees, compensation structure for non-employee directors.
• Auditors: Ratification of KPMG LLP as the independent registered public accounting firm.

Next Steps

• Stockholders are to vote on the proposals at the 2026 Annual Meeting of Stockholders.
• Final voting results will be published in a Current Report on Form 8-K within four business days after the Annual Meeting.
• If the amendment to the 2020 Equity Incentive Plan is approved, the company will file a registration statement on Form S-8 to register the shares available for issuance under the plan.

Key Dates

Recommendation

This filing is a routine proxy statement for an annual meeting, outlining standard corporate governance proposals and an amendment to the equity incentive plan. While the amendment aims to support talent retention, the inclusion of pre-funded warrants in share reserve calculations raises potential dilution concerns. Without new financial or strategic performance data, a 'hold' recommendation is appropriate, pending further developments.

Keywords

Shattuck Labs, DEF 14A, Proxy Statement, Annual Meeting, Stockholder Vote, Director Election, Executive Compensation, Equity Incentive Plan, KPMG LLP, Corporate Governance